Clinical Importance of Drug-Drug Interactions

药物相互作用的临床重要性

• 批准号: 7287372
• 负责人: Sean Hennessy
• 金额: $ 47.41万
• 依托单位: UNIVERSITY OF PENNSYLVANIA
• 依托单位国家: 美国
• 财政年份: 2006
• 资助国家: 美国
• 起止时间: 2006-09-15 至 2011-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7287372
• 关键词: Address; Affect; Antibiotics; Antifungal Agents; Azoles; Caring; Case Study; Classification; Clinical; Consultations; Crossover Design; Data; Databases; Digoxin; Drug Interactions; Drug Kinetics; Drug Utilization Review; Elderly; Ensure; Epidemiologic Studies; Funding; Future; General Practices; Glipizide; Glyburide; Knowledge; Macrolides; Measures; Medicaid; Medical Records; Medicare; Numbers; Outcome; Outcome Measure; Outcome Study; Patients; Pharmaceutical Preparations; Pharmacology; Process; Public Health; Quinolones; Relative Risks; Research; Research Personnel; Resources; Risk; Safety; Sudden Death; Sulfonamides; Tetracycline; Tetracyclines; Text; Treatment Factor; Ventricular Arrhythmia; Warfarin; base; case control; computerized physician order entry; drug standard; improved; interest; knowledge base; programs; quality improvement organization

DESCRIPTION (provided by applicant): Drug-drug interactions (DDIs) are an important public health problem, especially in the elderly, who are the largest consumers of medications. Nearly all existing knowledge about the clinical importance of potential DDIs comes from pharmacokinetic studies or case reports, both of which have limited utility for identifying clinically important DDIs. As a result, there is a great deal of disagreement among standard DDI reference texts regarding the clinical importance of most potential DDIs. Systematic efforts such as drug utilization review programs and computerized physician order entry that seek to improve medication use depend entirely upon a valid set of clinical rules, and are thus severely hampered by this knowledge gap. To address these critical gaps in existing knowledge of the clinical importance of DDIs, the investigators will perform controlled epidemiologic studies of high-priority potential DDIs that have been selected based on a formal process involving consultation with an Expert Panel of clinicians and clinical pharmacologists. We will use and expand upon an existing, very large pharmacoepidemiologic database consisting of Medicaid data from five large programs, supplemented by Medicare data to ensure complete capture of outcomes in the elderly, together with the General Practice Research Database from the UK. We will examine the validity of our outcome measures using medical record review. Our research strategy will include nested case-control and case-crossover designs, and will yield relative risks, risk differences, and number needed to harm (NNH). Patient and treatment factors associated with developing the adverse outcome of interest will be studied. The results of this study will have important implications for public health, clinical care, and the elucidation of the pharmacology of DDIs, and will serve as a basis for future studies examining factors not recorded in administrative and medical records data.

药物相互作用（DDI）是一个重要的公共卫生问题，尤其是在老年人中，他们是药物的最大消费者。几乎所有关于潜在DDI临床重要性的现有知识都来自药代动力学研究或病例报告，这两种研究对识别临床重要DDI的效用有限。因此，标准DDI参考文本中关于大多数潜在DDI的临床重要性存在很大分歧。系统性的努力，如药物利用审查计划和计算机化的医生订单输入，寻求改善药物使用完全依赖于一套有效的临床规则，因此严重阻碍了这种知识差距。为了解决DDI临床重要性的现有知识中的这些关键差距，研究者将对高优先级潜在DDI进行对照流行病学研究，这些DDI是根据与临床医生和临床药理学家专家小组协商的正式流程选择的。我们将使用并扩展现有的非常大的药物流行病学数据库，该数据库由来自五个大型项目的医疗补助数据组成，并辅以医疗保险数据，以确保完全捕获老年人的结果，以及英国的全科医学研究数据库。我们将使用病历审查来检查我们的结果指标的有效性。我们的研究策略将包括嵌套病例对照和病例交叉设计，并将产生相对风险，风险差异和伤害所需数量（NNH）。将研究与发生关注的不良结局相关的患者和治疗因素。本研究的结果将对公共卫生、临床护理和DDI药理学的阐明产生重要影响，并将作为未来研究的基础，研究管理和医疗记录数据中未记录的因素。